Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yohannes Gemechu

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
American Journal of Physiology. Gastrointestinal and Liver Physiology|July 24, 2025
Genetic disruption of <i>hnRNPI</i> reveals a microbial-metabolic axis in colitis-associated cancerYohannes Gemechu, Mengistu Lemecha
Trends in Molecular Medicine|December 9, 2024
Science around the worldBoris Cheval, Yohannes Gemechu, Parastoo Shahrouzi, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 8, 2016
Rabex-5 is a lenalidomide target molecule that negatively regulates TLR-induced type 1 IFN productionDavid Millrine, Mami Tei, Yohannes Gemechu, et al.
Trends in Molecular Medicine|May 31, 2024
Immunomodulatory drugs: a promising clinical ally for cancer immunotherapyAbigail Colley, Timothy Brauns, Ann E Sluder, et al.
Trends in Immunology|June 14, 2024
Targeting metabolic pathways to counter cancer immunotherapy resistanceYuki Agarwala, Timothy A Brauns, Ann E Sluder, et al.
International Journal of Preventive Medicine|August 4, 2011
Polymerase chain reaction (PCR) assay for rapid diagnosis and its role in prevention of human brucellosis in Punjab, IndiaMoti Yohannes Gemechu, Jatinder Paul Singh Gill, Anil Kumar Arora, et al.
Trends in Cancer|December 13, 2024
Intratumoral immune cell manipulations as a strategy to enhance cancer vaccine efficiencyJames Adeosun, Mohammad Omar Faruk Shaikh, Timothy Brauns, et al.
International Immunology|February 12, 2016
Immunomodulatory drugs inhibit TLR4-induced type-1 interferon production independently of Cereblon via suppression of the TRIF/IRF3 pathwayDavid Millrine, Haruhiko Miyata, Mami Tei, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 31, 2018
Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugsYohannes Gemechu, David Millrine, Shigeru Hashimoto, et al.
Cancer Letters|August 14, 2021
The novel long noncoding RNA AU021063, induced by IL-6/Arid5a signaling, exacerbates breast cancer invasion and metastasis by stabilizing Trib3 and activating the Mek/Erk pathwayKishan Kumar Nyati, Shigeru Hashimoto, Shailendra Kumar Singh, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
American Journal of Physiology. Gastrointestinal and Liver Physiology|July 24, 2025
Genetic disruption of <i>hnRNPI</i> reveals a microbial-metabolic axis in colitis-associated cancerYohannes Gemechu, Mengistu Lemecha
Trends in Molecular Medicine|December 9, 2024
Science around the worldBoris Cheval, Yohannes Gemechu, Parastoo Shahrouzi, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 8, 2016
Rabex-5 is a lenalidomide target molecule that negatively regulates TLR-induced type 1 IFN productionDavid Millrine, Mami Tei, Yohannes Gemechu, et al.
Trends in Molecular Medicine|May 31, 2024
Immunomodulatory drugs: a promising clinical ally for cancer immunotherapyAbigail Colley, Timothy Brauns, Ann E Sluder, et al.
Trends in Immunology|June 14, 2024
Targeting metabolic pathways to counter cancer immunotherapy resistanceYuki Agarwala, Timothy A Brauns, Ann E Sluder, et al.
International Journal of Preventive Medicine|August 4, 2011
Polymerase chain reaction (PCR) assay for rapid diagnosis and its role in prevention of human brucellosis in Punjab, IndiaMoti Yohannes Gemechu, Jatinder Paul Singh Gill, Anil Kumar Arora, et al.
Trends in Cancer|December 13, 2024
Intratumoral immune cell manipulations as a strategy to enhance cancer vaccine efficiencyJames Adeosun, Mohammad Omar Faruk Shaikh, Timothy Brauns, et al.
International Immunology|February 12, 2016
Immunomodulatory drugs inhibit TLR4-induced type-1 interferon production independently of Cereblon via suppression of the TRIF/IRF3 pathwayDavid Millrine, Haruhiko Miyata, Mami Tei, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 31, 2018
Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugsYohannes Gemechu, David Millrine, Shigeru Hashimoto, et al.
Cancer Letters|August 14, 2021
The novel long noncoding RNA AU021063, induced by IL-6/Arid5a signaling, exacerbates breast cancer invasion and metastasis by stabilizing Trib3 and activating the Mek/Erk pathwayKishan Kumar Nyati, Shigeru Hashimoto, Shailendra Kumar Singh, et al.
Pageof 2